PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jmedgeneJournal of Medical GeneticsVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Med Genet. 2007 December; 44(12): 779–783.
PMCID: PMC2652815

GATA4 sequence variants in patients with congenital heart disease

Abstract

Background

Recent reports have identified mutations in the transcription factor GATA4 in familial cases of cardiac septal defects. The prevalence of GATA4 mutations in the population of patients with septal defects is unknown. Given that patients with septal and conotruncal defect can share a common genetic basis, it is unclear whether patients with additional types of CHD might also have GATA4 mutations.

Aims

To explore these questions by investigating a large population of 628 patients with either septal or conotruncal defects for GATA4 sequence variants.

Methods

The GATA4 coding region and exon–intron boundaries were investigated for sequence variants using denaturing high‐performance liquid chromatography or conformation‐sensitive gel electrophoresis. Samples showing peak or band shifts were reamplified from genomic DNA and sequenced.

Results

Four missense sequence variants (Gly93Ala, Gln316Glu, Ala411Val, Asp425Asn) were identified in five patients (two with atrial septal defect, two with ventricular septal defect and one with tetralogy of Fallot), which were not seen in a control population. All four affected amino acid residues are conserved across species, and two of the sequence variants lead to changes in polarity. Ten synonymous sequence variants were also identified in 18 patients, which were not seen in the control population.

Conclusions

These data suggest that non‐synonymous GATA4 sequence variants are found in a small percentage of patients with septal defects and are very uncommonly found in patients with conotruncal defects.

Congenital heart disease (CHD) is one of the most common major birth defects, occurring in 4–8 per 1000 live births.1,2 Despite its prevalence and clinical significance, the aetiology of CHD remains largely unknown. The available data suggest that the disease aetiology is complex, involving multiple genetic and environmental factors.3,4 Fetal heart development is regulated by a group of highly conserved transcription factors, including NKX2.5, TBX5 and GATA4.5 Mutations in NKX2.5 have been identified in familial and sporadic non‐syndromic congenital heart disease (with or without atrioventricular block), including septal and conotruncal defects.6,7,8,9 Recent reports have identified GATA4 mutations in patients with predominantly familial cardiac septal defects.10,11,12,13,14GATA4 maps to a region of chromosome 8, of which deletions have variable association with CHD.15,16,17 Given that patients with septal and conotruncal defects can share a common genetic basis, it is possible that patients with other types of CHD also have GATA4 mutations. To explore these questions, and to correlate genotype with phenotype, a large cohort of 628 subjects with septal and conotruncal defects was investigated for GATA4 sequence variants.

Methods

Study cohort

Subjects were drawn from a cohort of patients recruited prospectively into genetic studies of congenital heart disease (table 11).). Informed consent was obtained from study participants in accordance with protocols approved by the Institutional Review Board for Human Research at The Children's Hospital of Philadelphia or at the Oregon Health and Science University (Oregon Registry of Congenital Heart Defects). Patients were invited to enrol in the study regardless of gender, race or ethnicity with no selection for or against familial CHD. Subjects with either atrial or ventricular septal defects (ASD or VSD respectively) or conotruncal anomalies were included. Specifically, patients with either a secundum or sinus venosus type ASD were included, whereas those with a primum ASD (endocardial cushion defect) were excluded. Patients with a perimembranous, posterior malalignment or conoseptal hypoplasia type VSD were included, whereas those with only a muscular or endocardial cushion type VSD were excluded. Patients with conotruncal defects, or anomalies of the right or left sided outflow tract of the heart, were recruited including those with: tetralogy of Fallot (TOF), truncus arteriosus (TA), interrupted aortic arch (IAA), double‐outlet right ventricle (DORV) or D‐transposition of the great arteries (D‐TGA). A small group of patients with L‐transposition of the great arteries (L‐TGA) or rare outflow tract defects was also investigated. Except for patients with ASD, all patients were tested for chromosome 22q11 deletion. Patients with chromosome 22q11 deletion, trisomy 21 or other identified chromosomal anomaly were excluded. Cardiovascular diagnoses were confirmed by attending paediatric cardiologists who reviewed echocardiograms and/or echocardiogram reports, cardiac catheterisation reports, and surgical notes if applicable. Family history of CHD was ascertained by a genetic counsellor by oral history, and confirmed by medical records when available. An effort was made to obtain parental DNA for sequence analysis in all patients found to have a non‐synonymous GATA4 sequence variant. Medical records of patients with a non‐synonymous GATA4 sequence variant were reviewed to determine whether any non‐cardiac congenital malformations or recognised genetic syndrome was present.

Table thumbnail
Table 1 Characteristics of study cohort

Control subjects

In total, 159 control subjects (48 African American, 78 European American, and 33 Hispanic American) with no reported cardiac phenotype were sequenced for variants in GATA4, and have been described previously.18 The DNA samples were obtained from the Dallas Heart Study repository at University of Texas Southwestern Medical Center. A low high‐density lipoprotein phenotype was found in 64 of the controls. An additional 105 control subjects of mixed but unspecified ethnicities were tested for sequence variants (Ala411Val, Asp425Asn) in exon 6 by conformation‐sensitive gel electrophoresis (CSGE).

Testing for sequence variants

The GATA4 gene is located on chromosome 8p23.1‐p22 and consists of six coding exons (NM_002052). We segmented the coding region, exon–intron junctions and part of the 3′ untranslated sequence of the gene (a scanned region of 1706 bp in total) into seven target sequences (table 22)) suitable for denaturing high‐performance liquid chromatography (DHPLC) (WAVE, Transgenomics Inc, Omaha, Nebraska, USA)19 or CSGE analysis. Each target sequence was amplified from genomic DNA by PCR. The PCR contained 20 ng genomic DNA amplified in a 30 μl reaction containing 1.5 U HotStar Taq polymerase and 1× HotStar Taq PCR Buffer (Qiagen Inc., Valencia, California, USA), 1.5 mmol/l MgCl2, 125 μmol/l of each dNTP (Roche, Germany) and 1 μmol/l of each PCR primer. All reactions started with 2 minutes at 95°C followed by 38–40 cycles of 45 seconds at 95°C, 30 seconds at 61°C or 63°C and 45 seconds at 72°C, and finished with a 10‐minute extension period at 72°C. PCR products were then examined for sequence alterations by DHPLC (n = 504) or CSGE (n = 124) analysis. Samples that showed peak or band shifts were reamplified from genomic DNA and then sequenced with an automated cycle sequencer in both directions (ABI BigDye Taq FS Terminator V.3.1; ABI Prism 3100sequencer, Applied Biosystems, Foster City, California, USA).

Table thumbnail
Table 2 Primers for GATA4

Results

Non‐synonymous sequence variants

Four sequence variants conferring a change in the encoded amino acid (Gly93Ala, Gln316Glu, Ala411Val, Asp425Asn) were identified in 5 patients (table 33),), and were not seen in 159 control subjects. One of these variants, Ala411Val, was previously reported in a patient with cardiac hypertrophy.20 However, neither this variant nor that seen in two of the current study subjects (Asp425Asn) were seen in an additional 105 control subjects. All four sequence variants change an amino acid conserved in mouse and rat. Using two programs (SIFT (Sorting Intolerant From Tolerant)21,22 and PolyPhen23,24), which predict whether an amino acid substitution affects protein function, two of the variants (Gln316Glu and Asp425Asn) are expected to affect protein function. One of the variants, Gln316Glu, maps to the nuclear localisation signal region of GATA4 (fig 11).

Table thumbnail
Table 3 Non‐synonymous sequence variants
figure mg52183.f1
Figure 1 Location of GATA4 sequence variants identified in study cohort. Schema of GATA4 with exons (n = 6) and functional domains. Red, non‐synonymous sequence variants; black, synonymous sequence variants; green, previously ...

Four of the five patients with non‐synonymous sequence variants had septal defects, and the fifth had tetralogy of Fallot (table 33).). Only one subject (Gln316Glu) had additional cardiac defects including small muscular VSDs and mild pulmonary valve stenosis. Review of medical records found that this subject (Gln316Glu) also had additional non‐cardiac anomalies, including hydrocephalus and developmental delay. The other four subjects had no other reported malformations or medical issues. None of the five subjects was reported to have cardiac conduction abnormalities or arrhythmias.

The patient carrying the Gly93Ala alteration was identified as having an ethnic ancestry of >1 race. The patient with the Gln316Glu alteration is Native American/Hispanic. The other three patients are of European American descent (Caucasian).

Characterisation of relatives

There was no family history of CHD in three patients carrying an alteration (Gly93Ala, Ala411Val). Another patient (Asp425Asn) had a vague history of CHDs: one sibling with heart and lung anomalies was miscarried, one paternal cousin had an abnormal valve and another had tachycardia. A distant family member died early in life with a “blue spell”, which may have resulted from unrepaired tetralogy of Fallot. The family history was unavailable for one subject (Gln316Glu).

If available, parental genomic DNA was tested for the sequence variant identified in the corresponding offspring. In two patients, reportedly unaffected mothers were carriers (table 33).

Synonymous sequence variants

Ten synonymous sequence variants were observed in 18 subjects, which were not seen in 159 control subjects (table 44).). Two of these sequence variants have been previously reported in two patients with cardiac hypertrophy.20 Nine of these alterations occurred within a conserved amino acid. Translationally silent alterations that change exonic splice enhancer (ESE) motifs have recently come under scrutiny because these sequence alterations can cause exon skipping. The list of “silent mutations” with confirmed association to genetic diseases is growing.25 Eight of the synonymous GATA4 sequence variants map into ESE motifs.26

Table thumbnail
Table 4 Synonymous sequence variants

Control subjects

Five sequence variants were observed both in controls and subjects (Asn352Asn (c.1056C→T), Ser371Ser (c.1113A→G), Ser377Gly (c.1129A→G), Val380Met (c.1138G→A), Pro407Pro (c.1221A→C). Three of these five sequence variants are listed in database SNP lists (Asn352Asn as rs3729855, Ser377Gly as rs3729856, Pro407Pro as rs7830178).

Discussion

This study sought to investigate the frequency with which GATA4 sequence variants occur in a large population with a variety of predominantly sporadic congenital heart disease. Despite reports of GATA4 mutations in some familial cases of septal defects, our data indicate that non‐synonymous sequence variants of GATA4 occur in only a small percentage of overall cases with septal anomalies and rarely in patients with conotruncal defects (table 55).). Two of three parents available for testing were found to carry the same sequence variant as the proband even though the same changes were not seen in control subjects. These individuals were reportedly unaffected, although this was not confirmed by echocardiogram. This finding is consistent with incomplete penetrance, a phenomenon commonly observed in complex traits and other genetic disorders characterised in part by CHD. Whether these particular missense sequence variants are disease‐causing, or increase the susceptibility to disease, or are even unrelated to the risk of disease is debatable in the absence of supportive functional data.

Table thumbnail
Table 5 Frequency of GATA4 sequence variants in 628 patients with CHD

Two of the four missense alterations (Gln316Glu and Asp425Asn) are predicted by SIFT21,22 and PolyPhen23,24 to affect protein function and hence, potentially alter phenotype. Gln316Glu maps to the nuclear localisation signal region of GATA4, which is important for DNA binding affinity and the transactivation of downstream targets. It is possible that all four missense alterations may be disease‐related, but the functional significance is difficult to demonstrate. Functional studies can help define the significance of these variants, but are themselves limited by the assay used, given the variable location of the changes in the coding region of the gene.

A surprising number of non‐synonymous sequence variants was found in our study cohort, but it is unclear whether these sequence variants are disease‐related. It was previously assumed that translationally silent sequence alterations would not have a phenotypic effect; however, there is increasing evidence that many human disease genes harbour exonic mutations, including silent mutations, that affect pre‐mRNA splicing.25,26,27 It is possible that silent GATA4 sequence variants alter gene function by modifying ESE or exonic splicing silencing sites. A recent query on AceView (National Center for Biotechnology Information) found that numerous isoforms of GATA4 are expressed in humans, although at present it appears that there is only one primary isoform in the heart. The production of several isoforms from the same transcriptional unit by various types of alternative splicing is common, occurring in 40–60% of all genes,28,29 and balancing these heterogeneous isoforms appears to have an important role in normal cell regulation. Other genes involved during fetal development appear to be very sensitive to changes in isoform balance. For instance, the alternative splicing of the WT1 gene, a transcription factor involved in growth and cell differentiation, generates four different isoforms.30,31 It was recently shown that environmental activation of the aryl hydrocarbon receptor pathway disrupts the heterogeneous balance of WT1 isoforms, and that this balance is extremely sensitive and necessary for correct nephrogenesis.32 It is possible that GATA4 is similarly sensitive to changes in isoform expression. In fact, animal data indicate that multiple aspects of cardiac morphogenesis and function are exquisitely sensitive to very small changes in GATA4 expression levels, and it has been hypothesised that altered GATA4 activity may contribute to CHD through both genetic and environmental factors.33,34 Another possibility is that synonymous sequence variants may alter the translational kinetics of mRNA, affecting final protein conformation, as was recently shown to occur with a translationally silent mutation in the multidrug resistance 1 (MDR1) gene.35,36 If some of the synonymous GATA4 sequence variants found in patients with conotruncal defects are functionally significant, then GATA4 alterations may make a greater contribution to the risk of conotruncal defects than is otherwise suggested by the notable rarity of non‐synonymous variants in this subset of patients.

Sequence variants of GATA4, synonymous or otherwise, were not identified in subjects with D‐TGA. Although the number of subjects is relatively small, this study supports previous observations that D‐TGA does not necessarily share a common genetic aetiology with other conotruncal defects or isolated perimembranous VSDs. For example, a 22q11 deletion is commonly identified in patients with tetralogy of Fallot, truncus arteriosus, interrupted aortic arch and perimembranous ventricular septal defects, but rarely identified in patients with D‐TGA.37 Likewise, mutations of NKX2.5, a molecular partner of GATA4, were found in a subset of patients with conotruncal or ventricular septal defects but not in the cohort with D‐TGA.8

In conclusion, four potentially disease‐related, missense GATA4 sequence variants were found in five patients with ASD, VSD, and TOF, which were not found in control subjects. Additional synonymous sequence variants were found in subjects with both septal and conotruncal defects (excluding those with D‐TGA). These data suggest that GATA4 sequence variants may be aetiologically important in a small subset of patients with septal defects and an even smaller subset of patients with conotruncal defects. These findings further underline the marked heterogeneity and aetiological complexity of congenital heart disease.

Acknowledgements

We would like to thank Dr D Srivastava and Dr W Benson for their helpful review of the study; Dr D McElhinney for primer design; E Geiger, W Huang and T Mason for technical assistance; and S Wielock, J Garbarini and S Edman for patient information.

Abbreviations

ASD - atrial septal defect

CHD - congenital heart disease

DHPLC - denaturing high‐performance liquid chromatography

CSGE - conformation‐sensitive gel electrophoresis

DORV - double‐outlet right ventricle

D‐TGA - D‐transposition of the great arteries

ESE - exonic splice enhancer

IAA - interrupted aortic arch

L‐TGA - L‐transposition of the great arteries

TA - truncus arteriosus

TOF - tetralogy of Fallot

VSD - ventricular septal defect

Footnotes

Funding: this work was supported by grants from the American Heart Association (0140151n) and National Institutes of Health (NHLBI) grant agencies (p50 hl62177, p50 hl74731) to E Goldmuntz.

Competing interests: none declared.

References

1. Ferencz C, Rubin J D, McCarter R J, Brenner J I, Neill C A, Perry L W, Hepner S I, Downing J W. Congenital heart disease: prevalence at livebirth. The Baltimore‐ Washington Infant Study. Am J Epidemiol 1985. 12131–36.36 [PubMed]
2. Perry L W, Neill C A, Ferencz C, Rubin J D, Loffredo C A. Infants with congenital heart disease: the cases. In: Ferencz C, Rubin JD, Loffredo CA, Magee CM, eds. Epidemiology of congenital heart disease: the Baltimore‐Washingtion Infant Study 1981–1989. Mount Kisco: Futura Publishing Company, Inc, 1993. 433–62.62
3. Nora J J, Nora A H. Recurrence risks in children having one parent with a congenital heart disease. Circulation 1976. 53701–702.702 [PubMed]
4. Ferencz C, Correa‐Villasenor A, Loffredo C A, Wilson P D. Malformations of the cardiac outflow tract. Genetic and environmental risk factors of major cardiovascular malformations: the Baltimore‐Washington Infant Study: 1981–1989. Armonk: Futura Publishing Company, Inc. 1997. 559–102.102
5. Srivastava D, Olson E N. A genetic blueprint for cardiac development. Nature 2000. 407221–226.226 [PubMed]
6. Schott J J, Benson D W, Basson C T, Pease W, Silberbach G M, Moak J P, Maron B J, Seidman C E, Seidman J G. Congenital heart disease caused by mutations in the transcription factor NKX2‐5. Science 1998. 281108–111.111 [PubMed]
7. Benson D W, Silberbach G M, Kavanaugh‐McHugh A, Cottrill C, Zhang Y, Riggs S, Smalls O, Johnson M C, Watson M S, Seidman J G, Seidman C E, Plowden J, Kugler J D. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest 1999. 1041567–1573.1573 [PMC free article] [PubMed]
8. McElhinney D B, Geiger E, Blinder J, Benson D W, Goldmuntz E. NKX2.5 mutations in patients with congenital heart disease. J Am Coll Cardiol 2003. 421650–1655.1655 [PubMed]
9. Goldmuntz E, Geiger E, Benson D W. NKX2.5 mutations in patients with tetralogy of fallot. Circulation 2001. 1042565–2568.2568 [PubMed]
10. Garg V, Kathiriya I S, Barnes R, Schluterman M K, King I N, Butler C A, Rothrock C R, Eapen R S, Hirayama‐Yamada K, Joo K, Matsuoka R, Cohen J C, Srivastava D. GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 2003. 424443–447.447 [PubMed]
11. Okubo A, Miyoshi O, Baba K, Takagi M, Tsukamoto K, Kinoshita A, Yoshiura K, Kishino T, Ohta T, Niikawa N, Matsumoto N. A novel GATA4 mutation completely segregated with atrial septal defect in a large Japanese family. J Med Genet 2004. 41e97 [PMC free article] [PubMed]
12. Sarkozy A, Conti E, Neri C, D'Agostino R, Digilio M C, Esposito G, Toscano A, Marino B, Pizzuti A, Dallapiccola B. Spectrum of atrial septal defects associated with mutations of NKX2.5 and GATA4 transcription factors. J Med Genet 2005. 42e16 [PMC free article] [PubMed]
13. Hirayama‐Yamada K, Kamisago M, Akimoto K, Aotsuka H, Nakamura Y, Tomita H, Furutani M, Imamura S, Takao A, Nakazawa M, Matsuoka R. Phenotypes with GATA4 or NKX2.5 mutations in familial atrial septal defect. Am J Med Genet A 2005. 13547–52.52 [PubMed]
14. Nemer G, Fadlalah F, Usta J, Nemer M, Dbaibo G, Obeid M, Bitar F. A novel mutation in the GATA4 gene in patients with tetralogy of Fallot. Hum Mutat 2006. 27293–294.294 [PubMed]
15. Devriendt K, Matthijs G, Van Dael R, Gewillig M, Eyskens B, Hjalgrim H, Dolmer B, McGaughran J, Brondum‐Nielsen K, Marynen P, Fryns J, Vermeesch J. Delineation of the critical deletion region for congenital heart defects, on chromosome 8p23.1. Am J Hum Genet 1999. 641119–1126.1126 [PubMed]
16. Giglio S, Graw S, Gimelli G, Pirola B, Varone P, Voullaire L, Lerzo F, Rossi E, Dellavecchia C, Bonaglia M, Digilio M, Giannotti A, Marino B, Carrozzo R, Korenberg J, Danesino C, Sujansky E, Dallapiccola B, Zuffardi O. Deletion of a 5‐cM region at chromosome 8p23 is associated with a spectrum of congenital heart defects. Circulation 2000. 102432–437.437 [PubMed]
17. Pehlivan T P B, Brueckner M, Garrett S, Slaugh R, Van Rheeden R, Wilson D B, Watson M S, Hing A V. GATA4 haploinsufficiency in patients with interstitial deletion of chromosome region 8p23.1 and congenital heart disease. Am J Med Genet 1999. 83201–206.206 [PubMed]
18. Schluterman M, Krysiak A, Kathiriya I, Abate N, Chandalia M, Srivastava D, Garg V. Screening and biochemical analysis of GATA4 sequence variations in patients with congenital heart disease. Am J Med Genet A 2007. 143817–823.823 [PubMed]
19. Kuklin A, Munson K, Gjerde D, Haefele R, Taylor P. Detection of single‐nucleotide polymorphisms with the WAVE DNA fragment analysis system. Genet Test 1997. 1201–206.206 [PubMed]
20. Poirier O, Nicaud V, McDonagh T, Dargie H J, Desnos M, Dorent R, Roizes G, Schwartz K, Tiret L, Komajda M, Cambien F. Polymorphisms of genes of the cardiac calcineurin pathway and cardiac hypertrophy. Eur J Hum Genet 2003. 11659–664.664 [PubMed]
21. Ng P C, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res 2001. 11863–874.874 [PubMed]
22. Ng P C, Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res 2003. 313812–3814.3814 [PMC free article] [PubMed]
23. Sunyaev S, Ramensky V, Bork P. Towards a structural basis of human non‐synonymous single nucleotide polymorphisms. Trends Genet 2000. 16198–200.200 [PubMed]
24. Sunyaev S, Ramensky V, Koch I, Lathe W, 3rd, Kondrashov A S, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001. 10591–597.597 [PubMed]
25. Cartegni L, Chew S L, Krainer A R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002. 3285–298.298 [PubMed]
26. Cartegni L, Wang J, Zhu Z, Zhang M Q, Krainer A R. ESEfinder: A web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003. 313568–3571.3571 [PMC free article] [PubMed]
27. Nielsen K B, Sorensen S, Cartegni L, Corydon T J, Doktor T K, Schroeder L D, Reinert L S, Elpeleg O, Krainer A R, Gregersen N, Kjems J, Andresen B S. Seemingly neutral polymorphic variants may confer immunity to splicing‐inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer. Am J Hum Genet 2007. 80416–432.432 [PubMed]
28. Modrek B, Lee C. A genomic view of alternative splicing. Nat Genet 2002. 3013–19.19 [PubMed]
29. Modrek B, Lee C J. Alternative splicing in the human, mouse and rat genomes is associated with an increased frequency of exon creation and/or loss. Nat Genet 2003. 34177–180.180 [PubMed]
30. Hastie N D. The genetics of Wilms' tumor – a case of disrupted development. Annu Rev Genet 1994. 28523–558.558 [PubMed]
31. Larsson S H, Charlieu J P, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V, Hastie N D. Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 1995. 81391–401.401 [PubMed]
32. Falahatpisheh M H, Ramos K S. Ligand‐activated Ahr signaling leads to disruption of nephrogenesis and altered Wilms' tumor suppressor mRNA splicing. Oncogene 2003. 222160–2171.2171 [PubMed]
33. Pu W T, Ishiwata T, Juraszek A L, Ma Q, Izumo S. GATA4 is a dosage‐sensitive regulator of cardiac morphogenesis. Dev Biol 2004. 275235–244.244 [PubMed]
34. Xin M, Davis C A, Molkentin J D, Lien C L, Duncan S A, Richardson J A, Olson E N. A threshold of GATA4 and GATA6 expression is required for cardiovascular development. Proc Natl Acad Sci U S A 2006. 10311189–11194.11194 [PubMed]
35. Komar A A. Genetics. SNPs, silent but not invisible. Science 2007. 315466–467.467 [PubMed]
36. Kimchi‐Sarfaty C, Oh J M, Kim I W, Sauna Z E, Calcagno A M, Ambudkar S V, Gottesman M M. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007. 315525–528.528 [PubMed]
37. Goldmuntz E, Clark B J, Mitchell L E, Jawad A F, Cuneo B F, Reed L, McDonald‐McGinn D, Chien P, Feuer J, Zackai E H, Emanuel B S, Driscoll D A. Frequency of 22q11 deletions in patients with conotruncal defects. J Am Coll Cardiol 1998. 32492–498.498 [PubMed]

Articles from Journal of Medical Genetics are provided here courtesy of BMJ Publishing Group